Autres langues Mendus AB

Actions

IMMU

SE0022239950

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 14:51:26 16/09/2026			Varia. 5j.	Varia. 1 janv.
6,350 ^SEK	-4,37%		-13,61%	+13,39%

11:25	Mendus lance un essai de phase précoce pour une thérapie combinée contre la leucémie myéloïde aiguë	MT
08:06	Mendus lance une étude de phase 1b avec le vididencel	FW

Autres langues

11:25	Mendus Launches Early-stage Trial for Acute Myeloid Leukemia Treatment Combo
08:01	Mendus announces initiation of the DIVA trial
14/09	Mendus draws under the second tranche of the Fenja Capital II A/S loan facility, extending cash runway into the second quarter of 2027
11/09	Mendus: Positive safety read-out from VITAL-CML trial
11/09	Mendus Reports Positive Read-Out For First Stage Vital-CML Trial
11/09	Mendus Reports 'Positive' Initial Safety Data for Vididencel in Chronic Myeloid Leukemia Trial
11/09	Mendus reports positive read-out for first stage VITAL-CML trial
24/08	Mendus (Q2 Review): Important CML Readout Near
20/08	Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	MENDUS AB INTERIM REPORT APRIL– JUNE 2026
13/08	Invitation to presentation of Mendus' second quarter 2026 financial report and business update
31/07	Change in number of shares and votes in Mendus AB (publ)
16/07	Mendus announces collaboration with the South Australian Health and Medical Research Institute (SAHMRI) to support preparation of the VITAL-TFR2 trial in chronic myeloid leukemia (CML)
16/07	Mendus AB and South Australian Health and Medical Research Institute Announce Collaboration to Support Preparation of the Vital-TFR2 Trial in Chronic Myeloid Leukemia
08/07	Mendus Completes First Stage Recruitment for Vididencel Trial
08/07	Mendus reports complete enrollment of the first stage of the VITAL-CML trial
08/07	Mendus AB Reports Complete Enrollment of the First Stage of the Vital-Cml Trial
23/06	Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares
10/06	Mendus AB (publ) repurchases outstanding warrants from Fenja
02/06	Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer
02/06	Mendus Reports Additional Positive Results from the Phase 1b Alison Trial in High-Grade Serous Ovarian Cancer
27/05	Mendus AB (publ) has resolved to transfer own shares
13/05	Mendus says vididencel combination potential confirmed
13/05	Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments
13/05	Mendus AB Presents Preclinical Data Confirming Combination Potential of Vididencel with Current and Upcoming Cml Treatments